Skip to Main Content

Paper Details

Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Oncotarget
14
2017
DS7423, GBM, GICs, GSC11, Glioblastoma, PI3K, PI3K/PTEN mutant glioma, PI3KCA, PTEN, U87, U87 glioma models, cancers, cell lines, chromosome 10, glioma, glioma cell lines, glioma tumor, glioma tumor cell lines, glioma-initiating cell (GIC) lines, mTOR, mice, patients, temozolomide, tumor, tumor suppressor gene, tumor suppressor gene PTEN, tumors
Author NameAffiliation
Dimpy KoulThe University of Texas MD Anderson Cancer Center
Siyuan ZhengThe University of Texas MD Anderson Cancer Center
Siyuan ZhengThe University of Texas MD Anderson Cancer Center
Erik P SulmanThe University of Texas MD Anderson Cancer Center
Erik P SulmanThe University of Texas MD Anderson Cancer Center
Wai-Kwan Alfred YungThe University of Texas MD Anderson Cancer Center
Wai-Kwan Alfred YungThe University of Texas MD Anderson Cancer Center
  • 1 - 7

Datasets

Release 1.2